Eli Lilly Strengthens Lead in Obesity Drug Race

By admin June 10, 2026 No comment

featured News Trending

Pharmaceutical giant Eli Lilly has reinforced its dominance in the rapidly growing obesity treatment market after presenting promising trial results for its experimental drug retatrutide. Data shared at the American Diabetes Association conference showed the once-weekly injection could deliver greater weight loss than any obesity drug currently available or under

Lower Prices for Branded Weight-Loss Pills Drive Patients Away from Compounded Alternatives

By admin May 21, 2026 No comment

featured News Trending

Lower pricing structures for oral weight-loss medications from Novo Nordisk and Eli Lilly are increasingly motivating patients to transition away from compounded drugs toward authentic branded options. Historically, the rampant shortages of branded injectable obesity treatments allowed compounding pharmacies to flourish by mixing their own personalized formulations.

Novo Nordisk Loses Wegovy-Era Gains

By admin February 24, 2026 No comment

featured News Trending

Shares of Novo Nordisk plunged more than 16%, erasing the remaining gains driven by its blockbuster weight-loss drug Wegovy. The sharp decline followed disappointing trial results for its next-generation obesity treatment CagriSema, which underperformed a rival therapy from Eli Lilly. The drop pushed Novo’s valuation sharply lower, extending a massive fall from its 2024

Obesity Drug Market Outlook Narrows as Prices Fall and Competition Rises

By admin February 2, 2026 No comment

featured News Trending

The long-standing expectation that the global obesity drug market would reach $150 billion within the next decade is becoming less certain as prices for leading GLP-1 treatments from Novo Nordisk and Eli Lilly decline in the United States. Analysts say intensifying competition, the rise of cash-pay consumers, and the prospect of new drugs and generics […]

Novo’s Wegovy Weight-Loss Pill Shows Strong Early Momentum Against Lilly

By admin January 17, 2026 No comment

featured News Trending

Novo Nordisk’s newly launched Wegovy weight-loss pill has shown encouraging early uptake in the United States, according to analysts citing initial prescription data. About 3,071 retail prescriptions were filled in the first four days after the January 5 launch, offering a first glimpse of performance for the first oral GLP-1 weight-loss drug to reach the […]